文献速递支持与姑息治疗头颈与中枢神经肿瘤泌尿男性生殖肿瘤

抗逆转录病毒治疗时代卡波西肉瘤后第二原发癌模式的变化

Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究利用SEER数据库9个登记处1973年至2013年的纵向数据,纳入14905例卡波西肉瘤患者,分析艾滋病前时代、高效抗逆转录病毒治疗前时代及高效抗逆转录病毒治疗时代第二原发癌的发生情况。结果显示,从高效抗逆转录病毒治疗前时代到高效抗逆转录病毒治疗时代,卡波西肉瘤后发生任何肿瘤的标准化发病比从3.36显著降至1.94,但急性淋巴细胞白血病、舌癌和阴茎癌的标准化发病比在高效抗逆转录病毒治疗时代升高。作者认为应对卡波西肉瘤患者密切监测和筛查这些第二原发癌。

要点

  • 卡波西肉瘤后发生任何肿瘤的标准化发病比从高效抗逆转录病毒治疗前时代的3.36降至高效抗逆转录病毒治疗时代的1.94
  • 高效抗逆转录病毒治疗时代,肛门癌、霍奇金淋巴瘤、非霍奇金淋巴瘤和肝癌仍与卡波西肉瘤相关
  • 高效抗逆转录病毒治疗时代新增显著升高的第二原发癌包括舌癌、阴茎癌和急性淋巴细胞白血病

核心结论

  • 卡波西肉瘤后第二原发癌的总体风险显著下降。
  • 与高效抗逆转录病毒治疗前时代相比,急性淋巴细胞白血病、舌癌和阴茎癌在高效抗逆转录病毒治疗时代越来越常见。
  • 作者认为对卡波西肉瘤患者密切监测和筛查这些第二原发癌是可取的。

研究设计与样本

  • 研究使用监测、流行病学和最终结果(SEER)数据库9个癌症登记处的纵向数据,识别1973年1月至2013年12月诊断的卡波西肉瘤病例。
  • 分析时间为2016年11月至2017年2月。
  • 共纳入14905例诊断卡波西肉瘤的个体,其中13721例(92.1%)诊断时年龄小于65岁,14356例(96.3%)为男性。
  • 第二原发癌仅纳入卡波西肉瘤诊断后2个月诊断的病例。
  • 计算艾滋病前时代(1973-1979年)、高效抗逆转录病毒治疗前时代(1980-1995年)和高效抗逆转录病毒治疗时代(1996-2013年)新发第二原发癌的标准化发病比(SIR)。

主要发现

  • 1980年至1995年,直肠癌SIR为2.01(95%CI,1.00-3.60),肛门癌SIR为49.70(95%CI,33.53-70.94),肝癌SIR为4.98(95%CI,2.79-8.22),宫颈癌SIR为13.70(95%CI,2.82-40.03),霍奇金淋巴瘤SIR为6.40(95%CI,2.76-12.60),非霍奇金淋巴瘤SIR为48.97(95%CI,44.85-53.36)。
  • 1996年至2013年,肛门癌、霍奇金淋巴瘤、非霍奇金淋巴瘤和肝癌仍与卡波西肉瘤相关,并新增以下显著SIR:舌癌SIR为6.99(95%CI,3.20-13.27),阴茎癌SIR为10.28(95%CI,1.24-37.13),急性淋巴细胞白血病SIR为17.62(95%CI,3.63-51.49)。
  • 从高效抗逆转录病毒治疗前时代到高效抗逆转录病毒治疗时代,卡波西肉瘤后发生任何肿瘤的SIR从3.36显著降至1.94。

临床怎么用

  • 作者认为对卡波西肉瘤患者密切监测和筛查急性淋巴细胞白血病、舌癌和阴茎癌等第二原发癌是可取的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Studies performed in the 1980s and early 1990s have shown that people who develop Kaposi sarcoma (KS) are at higher risk of developing other cancers. The demographics of those affected with human immunodeficiency virus (HIV)/AIDS and KS have changed, and individuals with HIV/AIDS and KS now live longer. OBJECTIVES: To test the hypothesis that the secondary cancers developing in patients with KS have changed in recent years and to assess the risk of secondary cancers after KS in different periods. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal data from 9 cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database were used to identify cases of KS diagnosed from January 1973 to December 2013. The dates of the analysis were November 2016 to February 2017. MAIN OUTCOMES AND MEASURES: The primary outcome was the development of secondary cancers in individuals with KS. Secondary cancers were considered only if diagnosed 2 months after a diagnosis of KS. Standardized incidence ratios (SIRs) were calculated for the development of new secondary cancers in the pre-AIDS era (1973-1979), pre-highly active antiretroviral therapy (HAART) era (1980-1995), and HAART era (1996-2013). Stratified analysis was then performed on a subset of the cases diagnosed from 1996 to 2013 based on age at diagnosis (<65 and ≥65 years), latency period between KS and the development of secondary cancers (1 year, 2-5 years, >5 to 10 years, and >10 years), and registries with higher vs lower reported rates of HIV/AIDS. RESULTS: Among 14 905 individuals with diagnosed KS, 13 721 (92.1%) were younger than 65 years at the time of diagnosis, and 14 356 (96.3%) were male. From 1980 to 1995, SIRs were 2.01 (95% CI, 1.00-3.60) for cancer of the rectum, 49.70 (95% CI, 33.53-70.94) for cancer of the anus, 4.98 (95% CI, 2.79-8.22) for cancer of the liver, 13.70 (95% CI, 2.82-40.03) for cancer of the cervix, 6.40 (95% CI, 2.76-12.60) for Hodgkin lymphoma, and 48.97 (95% CI, 44.85-53.36) for non-Hodgkin lymphoma. From 1996 to 2013, cancer of the anus, Hodgkin lymphoma, non-Hodgkin lymphoma, and cancer of the liver remained associated with KS, with the addition of the following significant SIRs: 6.99 (95% CI, 3.20-13.27) for cancer of the tongue, 10.28 (95% CI, 1.24-37.13) for cancer of the penis, and 17.62 (95% CI, 3.63-51.49) for acute lymphocytic leukemia. The SIR of developing any tumor after KS decreased significantly from 3.36 to 1.94 from the pre-HAART era to the HAART era. CONCLUSIONS AND RELEVANCE: There has been a significant decline in the overall risk of secondary cancers after KS. Certain cancers, including acute lymphocytic leukemia, cancer of the tongue, and cancer of the penis, are increasingly becoming more common in the HAART era compared with the pre-HAART era. Close monitoring and screening for these secondary cancers is desirable in patients with KS.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mukhtar F, Ilozumba M, Utuama O, et al. Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy. JAMA Oncol. 2018. PMID: 28837714. doi:10.1001/jamaoncol.2017.2395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。